'A fascinating and incisive study of the inner world of the pharmaceutical industry. A must-read for anyone interested in the relationship between drug pricing, regulation, and its impact on public health.' Sonia K. Katyal, Chancellor's Professor of Law, University of California, Berkeley
Introduction: big scandals, higher prices; 1. The winding road to generic entry; 2. 'Generation 1.0': the rise and fall of traditional pay-for-delay; 3. 'Generation 2.0': complicating pay-for-delay; 4. 'Generation 3.0': new tactics for active obstruction of generics; 5. 'Generation 3.0' continued: obstruction of regulatory pathways; 6. Empirical evidence of a citizen's pathway gone astray; Conclusion: a call for systematic reform.